HL 001 - Ube Industries
Alternative Names: HL-001 - Ube IndustriesLatest Information Update: 06 May 2022
At a glance
- Originator Ube Industries
- Developer HiLung; Ube Industries
- Class Antifibrotics; Small molecules; Thiophenes
- Mechanism of Action Lysophosphatidic acid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Idiopathic pulmonary fibrosis
Most Recent Events
- 31 Mar 2022 Ube Industries and HiLung enters into research agreement for HL 001 in idiopathic pulmonary fibrosis before March 2021
- 28 Mar 2022 Ube Industries and HiLung agree to co-develop HL 001 in idiopathic pulmonary fibrosis
- 28 Mar 2022 Ube Industries in collaboration with HiLung plans clinical trials by March 2024